	US 12,303,520 B2
	Aqueous nebulization composition
Ashley Daugherty, West Columbia, SC (US)
Assigned to Nephron Pharmaceuticals Corporation, West Columbia, SC (US)
Filed by Nephron Pharmaceuticals Corporation, West Columbia, SC (US)
Filed on May 27, 2022, as Appl. No. 17/826,602.
Application 17/826,602 is a continuation of application No. 16/103,630, filed on Aug. 14, 2018, granted, now 11,344,562.
Claims priority of provisional application 62/545,725, filed on Aug. 15, 2017.
Prior Publication US 2022/0288092 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/58 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/34 (2017.01); A61P 11/08 (2006.01)

CPC A61K 31/58 (2013.01) [A61K 9/0078 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01); A61P 11/08 (2018.01)]

23 Claims

1. A stable, homogeneous budesonide composition comprising:

i) 0.0125-0.15 wt. % budesonide;

ii) a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, present at a weight ratio of no more than 5:1, relative to the weight of budesonide in the composition; and

iii) at least 90 wt. % water.